Urea Cycle Disorders Market Size & Share, Trends, Epidemiology and Competitive Insights Report 2032 | Companies – Acer Therapeutics, Aeglea BioTherapeutics

DelveInsight’s “Urea Cycle Disorders – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Urea Cycle Disorders, historical and forecasted epidemiology as well as the Urea Cycle Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Urea Cycle Disorders Market Report 2032” report delivers an in-depth understanding of the Urea Cycle Disorders, historical and forecasted epidemiology as well as the Urea Cycle Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

A Urea Cycle Disorder (UCD) is a genetic disorder that results in a deficiency of some major enzymes in the urea cycle. These enzymes are responsible for removing ammonia from the bloodstream. The urea cycle involves a series of biochemical steps in which nitrogen, a waste product of protein metabolism, is changed to a compound called urea and removed from the blood. Normally, the urea is removed from the body through the urine. In urea cycle disorders, nitrogen builds up in the blood in the form of ammonia, a highly toxic substance, resulting in hyperammonemia (elevated blood ammonia). Ammonia then reaches the brain through the blood, where it can cause irreversible brain damage, coma, and/or death. The onset and severity of urea cycle disorders is highly variable. The severity correlates with the amount of urea cycle enzyme function.

A few of the enzymes which are involved in the Urea Cycle Disorder, collectively known as inborn errors of urea synthesis, or urea cycle enzyme defects; each is referred to by the initials of the missing enzyme: CPS1 (Carbamoyl Phosphate Synthetase), NAGS (N-Acetylglutamate Synthetase), OTC Deficiency (Ornithine Transcarbamylase), AS (Argininosuccinic Acid Synthetase (Citrullinemia)), ASL (Argininosuccinate Lyase (Argininosuccinic Aciduria)), and AG (Arginase).

In children with severe UCD, the symptoms will develop within the first 24 hours of life. Symptoms in children with mild or moderate UCD, who do not show symptoms until early childhood, may include: Vomiting, nausea, Mental confusion or hyperactive behaviour, Tired often and/or hard to awaken, Coma, etc.

View report: https://www.delveinsight.com/report-store/urea-cycle-disorders-market

Treatment is a lifelong process that doesn’t cure the condition, but it can effectively manage the symptoms. The child’s treatment probably will involve:

•Low protein, high-calorie diet


•Amino acid supplements

•Liver transplantation

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Study Period: 2019-2032

Urea Cycle Disorders Disease Overview 

The DelveInsight Urea Cycle Disorders market report gives a thorough understanding of the Urea Cycle Disorders by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Urea Cycle Disorders Epidemiology Key Findings:

“The estimated incidence of urea cycle disorders is 1 in 35,000 live births in the US or about 113 new patients per year.”

Key Urea Cycle Disorders pharma players:

1. Ultragenyx Pharmaceutical

2. Acer Therapeutics

3. Aeglea BioTherapeutics

4. Promethera Biosciences

5. Kaleido Biosciences  

Request a sample copy of the report: https://www.delveinsight.com/sample-request/urea-cycle-disorders-market

Urea Cycle Disorders Market Outlook

The Urea Cycle Disorders market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Urea Cycle Disorders market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

Recent advances in the treatment of inborn errors of urea synthesis have significantly decreased mortality. The treatment of urea cycle disorders consists of dietary management to limit ammonia production, in conjunction with medications and/or supplements that provide alternative pathways for the removal of ammonia from the bloodstream. The aim is to correct biochemical abnormalities and ensure adequate nutritional intake. Treatment involves compounds that increase the removal of nitrogen waste. These compounds convert nitrogen into products other than urea, which are then excreted; hence, the load on the urea cycle is reduced. The first compounds to be used were sodium benzoate and arginine. Later, phenylacetate was used, which has now been replaced by phenylbutyrate.

Hemodialysis is very effective at reducing plasma ammonia and should immediately be initiated if elevated hyperammonemia is observed. Ammonia scavenger medications such as Ammonul IV are also useful. Ammonul IV acts by removing glycine and glutamate from plasma thereby reducing their contribution to ammonia formation. 

According to DelveInsight, the Urea Cycle Disorders market in 7MM is expected to change in the study period 2019-2032.

Scope of the Report

The report covers the descriptive overview of Urea Cycle Disorders, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Urea Cycle Disorders epidemiology and treatment
An all-inclusive account of both the current and emerging therapies for Urea Cycle Disorders are provided
A detailed review of the Urea Cycle Disorders market; historical and forecasted is included in the report, covering drug outreach
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Urea Cycle Disorders market

Download sample pages of the report: https://www.delveinsight.com/sample-request/urea-cycle-disorders-market

Table of contents

1 Key Insight

2 Executive Summary of Urea Cycle Disorders

3 Urea Cycle Disorders Market Overview at a Glance

4 Disease Background and Overview: Urea Cycle Disorders

5 Case Reports

6 Urea Cycle Disorders Epidemiology and Patient Population

7 United States Epidemiology

8 EU5 Epidemiology

9 Japan Epidemiology

10 Current Urea Cycle Disorders Treatment and Medical Practices

11 Unmet needs

12 Urea Cycle Disorders Marketed Drugs

13 Urea Cycle Disorders Emerging Drugs

14 Urea Cycle Disorders 7MM Market Analysis

15 United States

16 EU-5 countries: Market Outlook

17 Japan Market Outlook

18 Urea Cycle Disorders Market Drivers

19 Urea Cycle Disorders Market Barriers

20 SWOT Analysis

21 Reimbursement and market access

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: